Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma - Kubiczkova - 2014 - Journal of Cellular and Molecular Medicine - Wiley Online Library
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma | Leukemia
PRODUCT CATALOGUE
Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms | BMC Cancer | Full Text
Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms | BMC Cancer | Full Text
Subcutaneous Velcade more tolerable in multiple myeloma trial | Fierce Pharma
Bortezomib (PS-341) | Proteasome Inhibitor | MedChemExpress
Breakthrough treatment with bortezomib for a patient with anti-NMDAR encephalitis - ScienceDirect
Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma | Blood Cancer Journal
Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma - Kubiczkova - 2014 - Journal of Cellular and Molecular Medicine - Wiley Online Library
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US | SpringerLink
Dose-dependent immunomodulatory effects of bortezomib in experimental autoimmune neuritis
Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma - Kubiczkova - 2014 - Journal of Cellular and Molecular Medicine - Wiley Online Library
View of Stability of Generic Formulations of Bortezomib 1.0 and 2.5 mg/mL in Vials and Syringes Stored at 4°C and Room Temperature (23°C or 25°C) | Canadian Journal of Hospital Pharmacy
Bortezomib (PS-341) | Proteasome Inhibitor | MedChemExpress
Population-based meta-analysis of bortezomib exposure–response relationships in multiple myeloma patients | Request PDF
Bortez Teva 3.5mg ג"מ 3.5 בורטז טבע אבקה להכת תמיסה להזרקה Powder for solution for injectio
Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms | BMC Cancer | Full Text
Bortezomib (PS-341) | Proteasome Inhibitor | MedChemExpress
Bortezomib-Teva®
Summary Public Assessment Report Generics Bortezomib Teva 1 mg and 3.5 mg powder for solution for injection Bortezomib HR/H/0102
Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
/cdn.vox-cdn.com/uploads/chorus_asset/file/6129353/bmj.png "Drug companies will earn $1.8 billion this year from cancer drugs that patients never take - Vox")
Drug companies will earn $1.8 billion this year from cancer drugs that patients never take - Vox
